A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Phase 1
420
about 6.8 years
18+
44 sites in AZ, CA, CO +21
What this study is about
This trial is testing a treatment called ziftomenib when combined with other medications to treat acute myeloid leukemia (AML). The goal is to see if the treatment is safe and well-tolerated.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Azacitidine
- 2.Take Cytarabine
- 3.Take Daunorubicin
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
azacitidine, cytarabine, daunorubicin, quizartinib, venetoclax
injection, subcutaneous, injection (Injection), oral (Oral Tablet), oral, oral (Oral Capsule)
Primary: Complete remission (CR) rate, Descriptive statistics of adverse events
Secondary: Cmax, Cmax of quizartinib, Cmax of venetoclax, EFS, Median DOR, Median EFS, Median OS, Tmax
Oncology